Loading...
XJPX
3183
Market cap219mUSD
Jul 10, Last price  
1,325.00JPY
1D
2.24%
1Q
2.55%
Jan 2017
31.32%
IPO
246.41%
Name

Win-Partners Co Ltd

Chart & Performance

D1W1MN
XJPX:3183 chart
P/E
17.20
P/S
0.40
EPS
77.03
Div Yield, %
4.01%
Shrs. gr., 5y
-0.58%
Rev. gr., 5y
7.79%
Revenues
90.39b
+11.03%
28,050,860,00028,127,098,00029,987,165,00029,258,841,00032,957,462,00033,912,558,00049,826,000,00050,558,000,00054,147,438,00057,760,490,00062,832,480,00069,775,788,00064,537,869,00062,123,939,00066,391,940,00070,854,470,00077,064,194,00081,410,300,00090,391,603,000
Net income
2.12b
+4.92%
940,129,000820,954,000902,297,000854,006,000955,316,000960,126,0001,840,000,0001,690,000,0002,111,656,0002,141,028,0003,005,542,0002,640,829,0001,872,588,0001,540,597,0001,831,893,0002,047,262,0001,835,759,0002,019,052,0002,118,327,000
CFO
2.93b
+42.40%
823,827,000866,216,0001,707,479,000616,405,000596,146,0001,737,691,0002,892,000,000-312,000,0002,294,373,0003,386,004,0001,343,723,0002,289,981,0003,219,666,0001,850,516,0002,622,058,000445,148,0003,043,527,0002,058,002,0002,930,560,000
Dividend
Mar 30, 202653 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1973 and headquartered in Tokyo, Japan, WIN-Partners Co., Ltd. leverages its subsidiaries to distribute a comprehensive range of medical devices to healthcare institutions, primarily across Japan. Its diverse product offerings include cutting-edge cardiovascular tools such as percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters. The company also supplies devices for cardiac rhythm management, like pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters. Furthermore, WIN-Partners provides structural and peripheral vascular products, including stent grafts, transcatheter heart valves, mechanical heart valves, and various stents and embolic coils. Rounding out its portfolio are diabetes management systems such as insulin pumps and continuous glucose monitoring devices, in addition to magnetic resonance imaging equipment.
IPO date
Apr 01, 2013
Employees
609
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT